ASCO: Gilead and Arcus's Cancer Immunotherapy Combo Faces Scrutiny Over Lower Survival Rates

Gilead Sciences, Inc. and Arcus Biosciences, Inc. unveiled updated results from a Phase II study of their experimental cancer immunotherapy combination, triggering further debate and speculation within the medical community. The anti-TIGIT/anti-PD-L1 combo, positioned as a potential first-line treatment for non-small cell lung cancer, garnered mixed reactions with its initial data release in December.